3. Producción
Browse
4 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Renewable energy based smart grid construction using hybrid design in control system with enhancing of energy efficiency of electronic converters for power electronic in electric vehicles(Hindawi Limited, 2022-01-01)The power electronic interface is critical in matching a distributed generation (DG) unit's characteristics to grid requirements as most DG technologies rely on renewable energy. Increased adoption of electric vehicles (EV) is seen as a positive step toward minimizing air pollution as well as carbon emissions. Rapid proliferation of electric vehicles as well as charging stations has exacerbated voltage quality as well as harmonic distortion difficulties, which harm the efficiency of combined renewable energy. This research proposes novel hybrid design techniques in control systems that enhance the energy efficiency of electronic converters for power electronics. The control system enhancement has been carried out using a hybrid energy storage electric convertor, and energy efficiency is improved using a synergetic battery reference adaptive controller. A plug-in hybrid electric vehicle (PHEV)'s internal combustion engine with a small photovoltaic (PV) module is utilised to assess a proposed control method which effectively regulates electric power on-grid by draining electricity from batteries during peak hours as well as then charging them during off-peak times, lowering the load on the converter as well as allowing electric vehicles to charge faster. Experimental results show the constant acceleration case obtained battery current of 92 Amps, ultracapacitor current of 89 Amps, charging voltage of 88 V, DC load current of 85 Amps, battery SOC of 72%, and the time-varying acceleration proposed technique obtained current of 94 Amps, and ultracapacitor current of 90 Amps, charging voltage of 90 V, DC load current of 82 Amps, battery SOC of 79%. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Therapeutic Potential of Mesenchymal Stem/Stromal Cells (MSCs)-Based Cell Therapy for Inflammatory Bowel Diseases (IBD) Therapy(BioMed Central Ltd, 2023-12-01)Recently, mesenchymal stem/stromal cells (MSCs) therapy has become an emerging therapeutic modality for the treatment of inflammatory bowel disease (IBD), given their immunoregulatory and pro-survival attributes. MSCs alleviate dysregulated inflammatory responses through the secretion of a myriad of anti-inflammatory mediators, such as interleukin 10 (IL-10), transforming growth factor-β (TGFβ), prostaglandin E2 (PGE2), tumor necrosis factor-stimulated gene-6 (TSG-6), etc. Indeed, MSC treatment of IBD is largely carried out through local microcirculation construction, colonization and repair, and immunomodulation, thus alleviating diseases severity. The clinical therapeutic efficacy relies on to the marked secretion of various secretory molecules from viable MSCs via paracrine mechanisms that are required for gut immuno-microbiota regulation and the proliferation and differentiation of surrounding cells like intestinal epithelial cells (IECs) and intestinal stem cells (ISCs). For example, MSCs can induce IECs proliferation and upregulate the expression of tight junction (TJs)-associated protein, ensuring intestinal barrier integrity. Concerning the encouraging results derived from animal studies, various clinical trials are conducted or ongoing to address the safety and efficacy of MSCs administration in IBD patients. Although the safety and short-term efficacy of MSCs administration have been evinced, the long-term efficacy of MSCs transplantation has not yet been verified. Herein, we have emphasized the illumination of the therapeutic capacity of MSCs therapy, including naïve MSCs, preconditioned MSCs, and also MSCs-derived exosomes, to alleviate IBD severity in experimental models. Also, a brief overview of published clinical trials in IBD patients has been delivered. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Intelligent Fog Computing Surveillance System for Crime and Vulnerability Identification and Tracing(IGI Global, 2023-01-01)IoT devices generate enormous amounts of data, which deep learning algorithms can learn from more effectively than shallow learning algorithms. The approach for threat detection may ultimately benefit fog computing or fog networking (fogging). The authors present a cutting-edge distributed DL method for detecting cyberattacks and vulnerability injection (CAVID) in this paper. In terms of the evaluation metrics tested in the tests, the DL model performs better than the SL models. They demonstrated a distributed DL-driven fog computing CAVID approach using the open-source NSLKDD dataset. A pre-trained SAE was utilised for feature engineering, whereas Softmax was employed for categorization. They used parametric evaluation for system assessment to evaluate the model in comparison to SL techniques. For scalability, accuracy across several worker nodes was taken into consideration. In addition to the robustness, effectiveness, and optimization of distributed parallel learning among fog nodes for enhancing accuracy, the findings demonstrate DL models exceeding classic ML architectures. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Designing Effective Multi-Target Drugs and Identifying Biomarkers in Recurrent Pregnancy Loss (RPL) Using In Vivo, In Vitro, and In Silico Approaches(MDPI, 2023-03-01)Recurrent pregnancy loss (RPL) occurs in approximately 5% of women. Despite an abundance of evidence, the molecular mechanism of RPL’s pathology remains unclear. Here, we report the protective role of polo-like kinase 1 (PLK1) during RPL. We aimed to construct an RPL network utilizing GEO datasets and identified hub high-traffic genes. We also investigated whether the expressions of PLK1 were altered in the chorionic villi collected from women with RPL compared to those from healthy early pregnant women. Gene expression differences were evaluated using both pathway and gene ontology (GO) analyses. The identified genes were validated using in vivo and in vitro models. Mice with PLK1-overexpression and PLK1-knockdown in vitro models were produced by transfecting certain plasmids and si-RNA, respectively. The apoptosis in the chorionic villi, mitochondrial function, and NF-κB signaling activity was evaluated. To suppress the activation of PLK1, the PLK1 inhibitor BI2536 was administered. The HTR-8/SVneo and JEG-3 cell lines were chosen to establish an RPL model in vitro. The NF-κB signaling, Foxo signaling, PI3K/AKT, and endometrial cancer signaling pathways were identified via the RPL regulatory network. The following genes were identified: PLK1 as hub high-traffic gene and MMP2, MMP9, BAX, MFN1, MFN2, FOXO1, OPA1, COX15, BCL2, DRP1, FIS1, TRAF2, and TOP2A. Clinical samples were examined, and the results demonstrated that RPL patients had tissues with decreased PLK1 expression in comparison to women with normal pregnancies (p < 0.01). In vitro, PLK1 knockdown induced the NF-κB signaling pathway and apoptosis activation while decreasing cell invasion, migration, and proliferation (p < 0.05). Furthermore, the in vivo model proved that cell mitochondrial function and chorionic villi development are both hampered by PLK1 suppression. Our findings revealed that the PLK1/TRAF2/NF-κB axis plays a crucial role in RPL-induced chorionic villi dysfunction by regulating mitochondrial dynamics and apoptosis and might be a potential therapeutic target in the clinic.